Cutting-edge DNA Synthesis Platform And Cost Reductions Will Power Future Market Expansion

AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Published
21 Mar 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$48.42
30.4% undervalued intrinsic discount
24 Jul
US$33.68
Loading
1Y
-25.7%
7D
-7.8%

Author's Valuation

US$48.4

30.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 8.78%

Shared on24 Apr 25
Fair value Decreased 1.41%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 2.25%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.

Shared on09 Apr 25
Fair value Decreased 3.16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.